NCT00368056

Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability

Effects of a Single Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability and Psychomotor/Memory Function in Patients With Primary Insomnia Compared to Placebo

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Sumitomo Pharma America, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

To assess next day driving ability and psychomotor/memory function following a single night time dose of eszopiclone in insomnia patients.

Detailed description

The study is a single centre, randomised, double blind, placebo controlled 2-way crossover design in a group of 32 male and female primary insomnia patients. The medications under investigation are eszopiclone and placebo. Patients will receive the study medications and placebo on the evening of Day 2 of each treatment period. Performance will be assessed on Day 3 of each treatment period. Each treatment period will be separated by at least a 7-day washout period. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Conditions

• Primary Insomnia

Interventions

Type	Name	Description
DRUG	Eszopiclone	eszopiclone 3 mg
DRUG	Placebo	Placebo tablet

Timeline

• Start date: 2005-04-01
• Primary completion: 2006-06-01
• Completion: 2006-06-01
• First posted: 2006-08-24
• Last updated: 2012-02-22

Locations

1 site across 1 country: United Kingdom